Skip to Main content Skip to Navigation
Preprints, Working Papers, ...

Making rareness count: testing and pricing orphan drugs

Abstract : This paper examines the testing and the pricing of orphan drugs, e.g. drugs for patients suffering from rare diseases. Due to the small size of these populations, orphan molecules question established evidentiary practices, namely randomized controlled trials (RCT) and health technology assessments (HTA), driven by numbers and statistical reasoning. Drawing on the notions of “statactivism” (Bruno et al. 2014) and “evidence-based activism” (Rabeharisoa et al. 2014), this paper shows how stakeholders in the field of rare diseases come to test a variety of solutions, ranging from adapting RCT and HTA on the fringe, advocating for exceptional procedures, to recomposing RCT and HTA from within. These initiatives offer new insights into the pricing of orphan drugs as a testing device of who is accountable for the evaluation of these molecules, and of how rare diseases are made to count for society at large.
Document type :
Preprints, Working Papers, ...
Complete list of metadata

Cited literature [16 references]  Display  Hide  Download
Contributor : Catherine Lucas Connect in order to contact the contributor
Submitted on : Wednesday, October 12, 2016 - 11:33:46 AM
Last modification on : Wednesday, November 17, 2021 - 12:33:10 PM
Long-term archiving on: : Friday, January 13, 2017 - 12:21:37 PM


WPi3_16-CSI-03_Rabeharisoa & D...
Files produced by the author(s)


  • HAL Id : hal-01379153, version 1


Vololona Rabeharisoa, Liliana Doganova. Making rareness count: testing and pricing orphan drugs. 2016. ⟨hal-01379153⟩



Record views


Files downloads